Allergic reactions of COVID-19 vaccine based on mRNA-LNP and its pharmacokinetics in vivo
10.16438/j.0513-4870.2022-1099
- VernacularTitle:mRNA-LNP新冠疫苗过敏反应及其体内药代动力学
- Author:
Chun-su LIANG
;
Wei ZUO
;
Li-ping DU
;
Bo ZHANG
- Publication Type:Research Article
- Keywords:
COVID-19 vaccine;
allergic reaction;
lipid nano particle;
mRNA;
pharmacokinetics
- From:
Acta Pharmaceutica Sinica
2023;58(4):867-874
- CountryChina
- Language:Chinese
-
Abstract:
Vaccination has been proved to be the most effective strategy to prevent the Corona Virus Disease 2019 (COVID-19). The mRNA vaccine based on nano drug delivery system (NDDS) - lipid nanoparticles (LNP) has been widely used because of its high effectiveness and safety. Although there have been reports of severe allergic reactions caused by mRNA-LNP vaccines, the mechanism and components of anaphylaxis have not been completely clarified yet. This review focuses on two mRNA-LNP vaccines, BNT162b2 and mRNA-1273. After summarizing the structural characteristics, potential allergens, possible allergic reaction mechanism, and pharmacokinetics of mRNA and LNP in vivo, this article then reviews the evaluation methods for patients with allergic history, as well as the regulations of different countries and regions on people who should not be vaccinated, in order to promote more safe injection of vaccines. LNP has become a recognized highly customizable nucleic acid delivery vector, which not only shows its value in mRNA vaccines, but also has great potential in treating rare diseases, cancers and other broad fields in the future. At the moment when mRNA-LNP vaccines open a new era of nano medicine, it is expected to provide some inspiration for safety research in the process of research, development and evaluation of more nano delivery drugs, and promote more nano drugs successfully to market.
